These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 27775715)

  • 41. BET proteins are a key component of immunoglobulin gene expression.
    Shim JM; Lee JS; Russell KE; Wiegman CH; Barnes PJ; Fear D; Adcock IM; Durham AL
    Epigenomics; 2017 Apr; 9(4):393-406. PubMed ID: 28322577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells.
    Kapp N; Stander XX; Stander BA
    Anticancer Drugs; 2018 Jun; 29(5):429-439. PubMed ID: 29561307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methylpyrrole inhibitors of BET bromodomains.
    Hasvold LA; Sheppard GS; Wang L; Fidanze SD; Liu D; Pratt JK; Mantei RA; Wada CK; Hubbard R; Shen Y; Lin X; Huang X; Warder SE; Wilcox D; Li L; Buchanan FG; Smithee L; Albert DH; Magoc TJ; Park CH; Petros AM; Panchal SC; Sun C; Kovar P; Soni NB; Elmore SW; Kati WM; McDaniel KF
    Bioorg Med Chem Lett; 2017 May; 27(10):2225-2233. PubMed ID: 28268136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
    Winter GE; Buckley DL; Paulk J; Roberts JM; Souza A; Dhe-Paganon S; Bradner JE
    Science; 2015 Jun; 348(6241):1376-81. PubMed ID: 25999370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.
    Xu Z; Sharp PP; Yao Y; Segal D; Ang CH; Khaw SL; Aubrey BJ; Gong J; Kelly GL; Herold MJ; Strasser A; Roberts AW; Alexander WS; Burns CJ; Huang DC; Glaser SP
    Leukemia; 2016 Jul; 30(7):1531-41. PubMed ID: 27055867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure.
    Qi J
    Cold Spring Harb Perspect Biol; 2014 Dec; 6(12):a018663. PubMed ID: 25452384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy.
    Antolic A; Wakimoto H; Jiao Z; Gorham JM; DePalma SR; Lemieux ME; Conner DA; Lee DY; Qi J; Seidman JG; Bradner JE; Brown JD; Haldar SM; Seidman CE; Burke MA
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32603312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.
    Ren C; Zhang G; Han F; Fu S; Cao Y; Zhang F; Zhang Q; Meslamani J; Xu Y; Ji D; Cao L; Zhou Q; Cheung KL; Sharma R; Babault N; Yi Z; Zhang W; Walsh MJ; Zeng L; Zhou MM
    Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7949-7954. PubMed ID: 30012592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells.
    Li J; Ma J; Meng G; Lin H; Wu S; Wang J; Luo J; Xu X; Tough D; Lindon M; Rioja I; Zhao J; Mei H; Prinjha R; Zhong Z
    Stem Cell Res; 2016 Sep; 17(2):212-221. PubMed ID: 27591477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRD4: a BET(ter) target for the treatment of AML?
    Valent P; Zuber J
    Cell Cycle; 2014; 13(5):689-90. PubMed ID: 24526121
    [No Abstract]   [Full Text] [Related]  

  • 54. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
    Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
    J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
    Devaraj SG; Fiskus W; Shah B; Qi J; Sun B; Iyer SP; Sharma S; Bradner JE; Bhalla KN
    Leukemia; 2016 Feb; 30(2):504-8. PubMed ID: 26148704
    [No Abstract]   [Full Text] [Related]  

  • 58. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
    Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
    Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.
    Niu Q; Liu Z; Alamer E; Fan X; Chen H; Endsley J; Gelman BB; Tian B; Kim JH; Michael NL; Robb ML; Ananworanich J; Zhou J; Hu H
    J Clin Invest; 2019 Jul; 129(8):3361-3373. PubMed ID: 31329163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.